首页> 外文OA文献 >PCV15 Comparison Of Apixaban, Dabigatran, Rivaroxaban, And Edoxaban In The Acute Treatment And Prevention Of Venous Thromboembolism: Systematic Review And Network Meta-Analysis

【2h】

PCV15 Comparison Of Apixaban, Dabigatran, Rivaroxaban, And Edoxaban In The Acute Treatment And Prevention Of Venous Thromboembolism: Systematic Review And Network Meta-Analysis

机译：阿哌沙班，达比加群，利伐沙班和依多沙班在急性静脉血栓栓塞症的急性治疗和预防中的PCV15比较：系统评价和网络Meta分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Cohen A.T.; Batson S.; Hamilton M.; Masseria C.; Mitchell S.; Phatak H.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons [J] . Hurst K. V., Lee R., Milosevic I., European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery . 2015,第1期

机译：回复：“新型口服抗凝药达比加群，利伐沙班，阿哌沙班和埃多沙班在静脉血栓栓塞的治疗和二级预防中的功效和安全性：III期临床试验的系统评价和荟萃分析”-外科医生的主要学习重点
2. Response to 'Re: Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials' [J] . Kakkos S. K., Kirkilesis G. I., Tsolakis I. A. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery . 2015,第3期

机译：对'Re：Kakkos等人的回应。新型口服抗凝药达比加群，利伐沙班，阿哌沙班和埃多沙班在静脉血栓栓塞的治疗和二级预防中的功效和安全性：III期试验的系统评价和荟萃分析
3. Re: 'Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials' [J] . Spanos K., Giannoukas A. D. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery . 2015,第3期

机译：回复：'Kakkos等。新型口服抗凝药达比加群，利伐沙班，阿哌沙班和埃多沙班在静脉血栓栓塞的治疗和二级预防中的功效和安全性：III期试验的系统评价和荟萃分析
4. Medical Effect of Venous Thromboembolism Prophylaxis Systems and Common Input Categories: Preliminary Findings from a Systematic Review [C] . Julian Varghese, Maren Kleine, Sophia Isabella Gessner, MEDINFO . 2017

机译：静脉血栓栓塞的医学效果预防系统和共同输入类别：系统评论中的初步调查结果
5. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for the prevention of stroke prophylaxis in atrial fibrillation. [D] . Harrington, Amanda. 2012

机译：阿哌沙班，达比加群，利伐沙班和华法林预防房颤预防中风的成本效益。
6. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis [O] . A. T. Cohen, M. Hamilton, S. A. Mitchell, 2010

机译：新型口服抗凝药阿哌沙班，达比加群，依多沙班和利伐沙班在初始和长期治疗及预防静脉血栓栓塞中的比较：系统评价和网络Meta分析
7. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. [O] . A T Cohen, M Hamilton, S A Mitchell, 2015

机译：新型口服抗凝剂阿哌沙班，达比加群，依沙沙班和利伐沙班在静脉血栓栓塞的初始和长期治疗和预防中的比较：系统评价和网络荟萃分析。

PCV15 Comparison Of Apixaban, Dabigatran, Rivaroxaban, And Edoxaban In The Acute Treatment And Prevention Of Venous Thromboembolism: Systematic Review And Network Meta-Analysis

著录项

相似文献

相关主题

期刊订阅